The framework has had a lukewarm reaction, with trade association EFPIA saying the policies are “not strong enough”.

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...

Novartis and Relation's target discovery deal falls under Novartis’ wider ploy to strengthen its immunology portfolio.

Zealand Pharma and OTR Therapeutics are to collaborate to discover and develop therapies for several targets in metabolic diseases.

Pfizer is set to cut several jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg.

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006 from Lynk Pharmaceuticals.

The UK's 14.5% drug rebate reduction may help to quell souring pharma sentiments, which stem from the nation's low spending on innovative drugs.

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American ...

Formycon and Zydus Lifesciences have entered into an exclusive licensing and supply agreement for FYB206 in the US and Canada ...

Biogen has received an NOC from Health Canada for Zurzuvae, a NAS, as a treatment for moderate or severe PPD in women.

Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.